Furthermore, we present existing and new treatment methods that are centered on CAFs, such as suppression of the paracrine pathway (e.g., IL-6/STAT3, TGF-β), depletion of CAFs lineages by targeting fibroblast activation protein (FAP), and conversion toward tumor-restraining CAFs. The gene discussed is TBX1; the disease is neoplasm.